Humacyte priced a $50 million stock offering of 47.6 million shares at $1.05 each. The capital raise came on the same day the company reported positive Phase 3 dialysis data. Proceeds will fund Symvess commercialization and a planned regulatory filing.
Humacyte priced a $50 million public offering of 47.6 million shares at $1.05 apiece, diluting existing holders by roughly 20 percent.
"These results reinforce the potential of our bioengineered human blood vessel to improve outcomes while addressing longstanding challenges in dialysis access," Shamik Parikh, chief medical officer at Humacyte, said, referring to positive Phase 3 data announced the same day.
The offering includes a 30-day underwriter option for an additional 7.1 million shares. Barclays, BTIG and Titan Partners are acting as joint book-running managers. The securities are offered under a shelf registration statement declared effective by the SEC on Sept. 22, 2025. Humacyte plans to use net proceeds to fund Symvess commercialization, a planned Biologics License Application supplement for hemodialysis, pipeline development and working capital.
The capital raise coincided with positive interim results from the V012 Phase 3 study of the acellular tissue engineered vessel in female dialysis patients. The ATEV met its primary endpoint with an average of 220 catheter-free days versus 129 for autologous arteriovenous fistula, a statistically significant result (p=0.00070). Patients receiving the ATEV incurred infections at a rate of six per 100 patient years, compared with 23 per 100 patient years for the AV fistula group. The company plans to file a supplemental BLA with the FDA during the second half of 2026.
The stock fell in after-hours trading on the dilution news. The $50 million raise, at a steep discount to recent levels, will test investor appetite for Humacyte's commercial-stage story. The company launched Symvess, its first FDA-approved product, in the first quarter of 2025 for extremity vascular trauma. Over 800,000 Americans live with end-stage kidney disease, and nearly 500,000 depend on hemodialysis, representing a significant market opportunity if the ATEV gains approval for dialysis access. The supplemental BLA filing, expected in the second half of 2026, is the next major catalyst for the stock.
This article is for informational purposes only and does not constitute investment advice.
